Disease:
 Neuroblastoma 
Species:

Rattus norvegicus (rat) 

Tissue:

Brain 

Morphology:

Epithelial 

Properties:

Adherent 

Medium:

DMEM + 10% FBS 

Subculture:

1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37°C 

Freezing Medium:

Complete culture medium supplemented with 5% (v/v) DMSO 

Biosafety Level:

 I 

Sterility:

Bacteria: Negative 

Yeast: Negative 

Mycoplasma: Negative 

Pathogens:

HIV: Negative 

Hepatitis B: Negative 

Hepatitis C: Negative 

Isoenzymes:
 Not known 
DNA Profile (STR):
 Not known 
Related cells by Organ:

B103 

LN-319 

SH-Sy5y cells 

U87MG cells 


References for B103 cells:

1. Hahn, C. G., Pawlyk, A. C., Whybrow, P. C., and Tejani-Butt, S. M. Differential expression of thyroid hormone receptor isoforms by thyroid hormone and lithium in rat GH3 and B103 cells. Biol Psychiatry, 45: 1004-1012, 1999. 

2. Han, J. Z., Lin, W., Lou, S. J., Qiu, J., and Chen, Y. Z. A rapid, nongenomic action of glucocorticoids in rat B103 neuroblastoma cells. Biochim Biophys Acta, 1591: 21-27, 2002. 

3. Hashimoto, M., Takenouchi, T., Rockenstein, E., and Masliah, E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem, 85: 1468-1479, 2003. 

4. Kawanabe, Y., Hashimoto, N., and Masaki, T. B103 neuroblastoma cells predominantly express endothelin ET(B) receptor; effects of extracellular Ca(2+) influx on endothelin-1-induced mitogenesis. Eur J Pharmacol, 425: 173-179, 2001. 

5. Pinto, C. S. and Seifert, R. Decreased GTP-stimulated adenylyl cyclase activity in HPRT-deficient human and mouse fibroblast and rat B103 neuroblastoma cell membranes. J Neurochem, 96: 454-459, 2006. 

6. Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H., Zuhowski, E. G., Pluim, D., Joseph, E., Hamburger, D. R., Working, P. K., Colbern, G., Tonda, M. E., Potter, D. M., and Eiseman, J. L. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol, 53: 329-336, 2004.